查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094742

前列腺健康市場－2026-2032年全球市場預測

Prostate Health Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，攝護腺健康市場將成長至 547.9 億美元，複合年成長率為 7.98%。

主要市場統計數據
基準年 2025 320.1億美元
預計年份：2026年 345.1億美元
預測年份 2032 547.9億美元
複合年成長率 (%) 7.98%

攝護腺健康是預防醫學、泌尿系統、腫瘤學、診斷、製藥、醫療設備、數位醫療和男性健康等領域的重中之重。良性攝護腺增生（BPH）、攝護腺炎、下泌尿道症狀和攝護腺癌等疾病給全球數百萬男性帶來沉重的臨床負擔，且其盛行率老齡化增加而顯著增加。攝護腺癌仍然是全球男性最常見的癌症之一，而良性攝護腺增生是老年男性泌尿道症狀的主要原因。這些疾病持續引發人們對早期檢測、風險分層、微創治療、個人化治療和長期生活品質管理的關注。

前列腺健康格局正受到人口老化、男性預防保健意識增強、臨床適用時廣泛應用前列腺特異性抗原 (PSA) 檢測、多參數磁振造影 (MRI) 普及以及靶向切片檢查方案日益廣泛應用等因素的影響。同時，醫療系統正致力於篩檢、對低風險前列腺癌進行積極後續觀察以及以患者為中心的決策來減少過度診斷和過度治療。遠距泌尿系統、居家尿路症狀追蹤、數位化療法和人工智慧影像技術的進步也正在改善醫療服務的連續性。

對於產業相關人員，商機遠不止於治療本身。最具競爭力的策略正在前列腺健康的各個方面湧現——包括教育、篩檢、診斷、影像學檢查、臨床檢測、藥物治療、外科手術和微創手術、治療後續觀察、康復以及健康支持。那些能夠將臨床證據、公平的醫療服務獲取、數位技術的應用以及可衡量的患者療效相結合的機構，最有可能在這個不斷發展的醫療保健領域中保持其重要性。

一項將重塑前列腺護理的變革性變革。

攝護腺健康生態系統正經歷一場變革，醫療模式正從被動的、以症狀為導向的治療轉向以精準醫療主導、以預防為導向、以結果為導向的管理。傳統上，許多男性只有在出現泌尿道症狀或篩檢結果異常後才開始尋求醫療協助。如今，臨床醫生擴大採用風險適應性方法，將年齡、家族病史、種族、PSA動態變化、影像學觀察、基因組指標、合併症以及患者意願等因素納入考量，以確定最合適的後續治療方案。

人工智慧對攝護腺健康的累積影響

人工智慧 (AI) 透過支援早期檢測、更一致的觀察解讀、簡化工作流程和個人化管理，正在對前列腺健康的整個價值鏈產生累積影響。在前列腺癌診斷中，AI 工具已被應用於 MRI觀察、病灶檢測、前列腺分割、切片檢查計劃、病理切片審查和風險分層。這些應用尤其重要，因為攝護腺影像和觀察解讀需要專業知識，而放射科醫師之間的差異會影響臨床決策。

前列腺健康市場的關鍵區域洞察

在亞太地區，人口快速老化、都市化加快、私人醫療服務普及率提高以及癌症意識增強，正在塑造人們對攝護腺健康的需求。然而，日本、韓國、中國、印度和澳洲等國家在篩檢率、磁振造影（MRI）普及率和泌尿系統基礎設施水準方面存在差異。日本和澳洲的診斷流程相對成熟，而中國和印度正在加強專科醫生網路建設，並在主要城市擴大先進影像設備的覆蓋範圍。該地區還面臨癌症意識水平差異、經濟負擔以及遍遠地區醫療服務可近性不足等挑戰，因此，擴充性的數位教育和分階段轉診模式顯得尤為重要。

針對攝護腺健康相關優先議題，針對特定族群的關鍵見解。

北約成員國與北美和歐洲先進的醫療保健體系存在顯著的重疊之處，這些體系涵蓋國防相關醫療保健系統、退伍軍人醫療保健、國家衛生服務和職業健康系統，為前列腺癌篩檢、倖存者護理以及老年男性人群的長期管理提供了獨特的途徑。儘管這些體係有助於規範預防性醫療保健的參與，但地方層級的醫療服務取得和分散問題仍然是重大挑戰。

各國對攝護腺醫療保健的深入了解

在中國，隨著人口老化和大型醫院採用先進的影像技術、機器人手術和腫瘤治療，攝護腺健康醫療體係正在迅速發展。然而，在許多非都市區，人們對攝護腺健康的認知不足，早期診斷的可近性也欠佳。美國在前列腺健康領域擁有世界領先的環境，這得益於其龐大的泌尿系統網路、廣泛普及的先進影像技術、積極的臨床試驗以及精準腫瘤學工具的廣泛應用。然而，黑人男性和醫療資源匱乏社區的前列腺癌發病率和死亡率差異仍然是一個重要的公共衛生問題。

為前列腺醫療產業的領導者提供的實用建議

行業領導者應優先考慮以循證醫學為基礎的前列腺健康解決方案，這些方案應涵蓋患者的整個就醫過程，從提高認知和篩檢意識，到診斷、治療、後續觀察和康復。首先，各機構應投資於經臨床驗證的教育項目，以減少恥辱感，並鼓勵男性及時就醫，例如出現泌尿系統症狀、對家族病史感到擔憂或對篩檢有疑問時。訊息需要符合文化背景，並針對高風險族群進行個人化客製化，例如老年男性和已知前列腺癌預後有差異的族群。

攝護腺健康分析的調查方法

本執行摘要採用系統化的二手調查方法撰寫，重點關注檢驗、資料支援且臨床可靠的資訊來源。該研究途徑整合了同行評審的醫學文獻、國際癌症和泌尿系統指南、公共衛生機構和監管機構的公告、臨床實踐指南、醫院流程文件以及權威衛生機構的流行病學參考資料。分析內容涵蓋攝護腺癌、良性攝護腺增生、攝護腺炎、下泌尿道症狀、影像檢查、切片檢查途徑、微創介入治療、數位醫療、人工智慧以及區域醫療保健服務取得趨勢。

結論：前列腺健康的未來

攝護腺健康正邁入一個新時代，其特徵是早期發現、精準診斷、微創治療、數位化應用以及對長期生活品質（QOL）的日益重視。應對攝護腺癌、良性攝護腺增生（BPH）、攝護腺炎和泌尿道症狀帶來的臨床負擔，仍需醫療服務提供者、政策制定者、保險公司、技術開發商和病患教育等各利害關係人的通力合作。最有意義的進展將來自於縮短診斷延遲、改善專科診療服務、擴大實證影像和人工智慧的應用，以及消除影響不同地區和人群治療結果的差異。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 攝護腺健康市場：依產品類型分類

  • 診斷試劑盒
    • 切片檢查設備
    • 造影
  • 製藥
    • 化療
    • 荷爾蒙療法
    • 免疫療法
    • 放射性藥物
  • 影像系統
    • 電腦斷層掃描（CT）
    • 磁振造影
    • 正子斷層掃描
    • 超音波
      • 經腹法
      • 經直腸

第8章：攝護腺健康市場：依適應症分類

  • 良性攝護腺增生
  • 攝護腺癌
  • 攝護腺炎

第9章：攝護腺健康市場：依技術類型分類

  • 數位病理學
    • 人工智慧驅動的分析
    • 全幻燈片成像
  • 影像分析軟體
  • 分子診斷
    • 生物標記檢測
    • 次世代定序面板
    • 聚合酵素鏈鎖反應（PCR）檢測

第10章：攝護腺健康市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院
  • 專科診所

第11章 攝護腺健康市場：依通路分類

  • 直接招標
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 攝護腺健康市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 攝護腺健康市場：依群體分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 攝護腺健康市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boston Scientific Corporation
  • Bracco SpA
  • Danaher Corporation
  • Eli Lilly And Company
  • Intuitive Surgical, Inc.
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • MDxHealth SA
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Nestle SA
  • Novartis AG
  • NOW Health Group, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • PROCEPT BioRobotics Corporation
  • Roche Holding AG
  • Sanofi SA
  • Siemens Healthineers AG
  • Teleflex Incorporated
  • Telix Pharmaceuticals Limited
  • Veracyte, Inc.
Product Code: MRR-8201ABF20E0C

The Prostate Health Market is projected to grow by USD 54.79 billion at a CAGR of 7.98% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 32.01 billion
Estimated Year [2026] USD 34.51 billion
Forecast Year [2032] USD 54.79 billion
CAGR (%) 7.98%

Prostate health has become a high-priority focus across preventive care, urology, oncology, diagnostics, pharmaceuticals, medical devices, digital health, and men's wellness. The clinical burden is substantial: benign prostatic hyperplasia (BPH), prostatitis, lower urinary tract symptoms, and prostate cancer affect millions of men globally, with prevalence increasing sharply with age. Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide, while BPH is a leading cause of urinary symptoms in aging male populations. These conditions are driving sustained attention toward earlier detection, risk stratification, minimally invasive treatment, personalized therapy, and long-term quality-of-life management.

The prostate health landscape is being shaped by demographic aging, rising awareness of men's preventive health, wider use of prostate-specific antigen testing where clinically appropriate, expanding access to multiparametric MRI, and stronger adoption of targeted biopsy pathways. At the same time, healthcare systems are seeking to reduce overdiagnosis and overtreatment by applying evidence-based screening, active surveillance for low-risk prostate cancer, and patient-centered decision-making. Growth in teleurology, home-based urinary symptom tracking, digital therapeutics, and AI-supported imaging interpretation is also improving continuity of care.

For industry stakeholders, the opportunity is not limited to treatment. The most competitive strategies are emerging across the full prostate health continuum: education, screening, diagnostics, imaging, laboratory testing, drug therapy, surgical and minimally invasive intervention, post-treatment monitoring, survivorship, and wellness support. Organizations that combine clinical evidence, equitable access, digital enablement, and measurable patient outcomes are best positioned to strengthen relevance in this evolving healthcare segment.

Transformative Shifts Reshaping Prostate Health Care

The prostate health ecosystem is undergoing transformative shifts as care models move from reactive symptom treatment toward precision-led, prevention-oriented, and outcomes-based management. Historically, many men entered the care pathway after developing urinary symptoms or receiving abnormal screening results. Today, clinicians are increasingly using risk-adapted approaches that incorporate age, family history, ethnicity, PSA kinetics, imaging findings, genomic indicators, comorbidities, and patient preference to determine the most appropriate next step.

One of the most important shifts is the mainstreaming of multiparametric MRI before prostate biopsy in many advanced healthcare systems. Clinical guidelines increasingly support MRI-informed pathways because they can improve detection of clinically significant disease while helping reduce unnecessary biopsies. Transperineal biopsy approaches are also gaining traction because they may lower infection risk compared with traditional transrectal approaches. In BPH, treatment is shifting beyond long-term medication and conventional surgery toward minimally invasive procedures designed to reduce symptom burden while preserving sexual function and shortening recovery time.

Consumer behavior is changing as well. Men are becoming more receptive to discreet digital engagement, virtual consultations, at-home education, and longitudinal symptom monitoring. However, stigma, low awareness, uneven access to urologists, and cultural barriers continue to limit timely care in many regions. The next phase of the prostate health landscape will be defined by integrated pathways that link primary care, urology, radiology, pathology, oncology, pharmacy, and digital platforms into a more coordinated patient experience.

Cumulative Impact of Artificial Intelligence on Prostate Health

Artificial intelligence is creating cumulative impact across the prostate health value chain by supporting earlier detection, more consistent interpretation, workflow efficiency, and personalized management. In prostate cancer diagnostics, AI-enabled tools are being applied to MRI interpretation, lesion detection, prostate segmentation, biopsy planning, pathology slide review, and risk stratification. These applications are particularly relevant because prostate imaging and pathology interpretation require specialized expertise, and variability between readers can affect clinical decisions.

AI can help standardize radiology workflows by identifying suspicious lesions, estimating prostate volume, assisting with PI-RADS-related assessments, and supporting fusion biopsy targeting. In pathology, digital image analysis can assist with tumor identification, grading support, and workload prioritization, although expert clinical validation and pathologist oversight remain essential. AI-driven clinical decision support is also being explored for predicting disease progression, guiding active surveillance, assessing recurrence risk, and optimizing follow-up intervals.

Beyond oncology, AI is increasingly relevant in BPH and lower urinary tract symptom management. Digital symptom scoring, wearable-linked urinary pattern analysis, chatbot-based education, and remote monitoring may help clinicians identify symptom progression and treatment response more efficiently. The cumulative value of AI will depend on high-quality datasets, transparency, regulatory compliance, bias mitigation, cybersecurity, interoperability with electronic health records, and prospective clinical validation. Industry leaders that deploy AI as a clinician-augmenting tool rather than a replacement for medical judgment are more likely to gain trust from providers, regulators, and patients.

Key Regional Insights Across Prostate Health Markets

In Asia-Pacific, prostate health demand is shaped by rapid population aging, urbanization, expanding private healthcare access, and rising cancer awareness, while countries such as Japan, South Korea, China, India, and Australia show different levels of screening adoption, MRI availability, and urology infrastructure. Japan and Australia have relatively mature diagnostic pathways, while China and India are strengthening specialist capacity and access to advanced imaging in major cities. The region also faces variability in awareness, affordability, and rural access, making scalable digital education and tiered referral models especially important.

Europe benefits from strong clinical guideline adoption, structured cancer care networks, and increasing use of MRI before biopsy, particularly in Western and Northern Europe. The European Union's emphasis on cancer planning, cross-border evidence standards, and health technology assessment supports quality improvement in prostate care. However, access differences persist across countries, especially in imaging capacity, surgical technology, and reimbursement for novel therapies.

North America remains one of the most advanced prostate health environments due to broad specialist availability, established urology networks, high use of PSA testing within guideline-based care, strong adoption of imaging-led diagnosis, and growing use of minimally invasive BPH procedures. The United States has extensive clinical trial activity and high uptake of advanced diagnostics, while Canada emphasizes publicly funded care pathways and evidence-based screening discussions. Health equity remains a critical issue across the region, particularly because prostate cancer outcomes differ by race, income, geography, and access to timely specialist care.

Latin America is characterized by growing awareness of men's health and increasing investment in oncology and urology services, but access remains uneven between major urban centers and rural or underserved communities. Brazil and Mexico are important care hubs, with public and private systems supporting different levels of diagnostic and treatment availability. Delayed presentation, limited specialist distribution, and affordability constraints continue to influence outcomes, creating opportunities for public education, telehealth-enabled triage, and cost-effective diagnostic strategies.

Across Africa, prostate cancer is a major men's health concern, with late-stage diagnosis common in many settings due to limited awareness, scarce specialist access, and constrained diagnostic infrastructure. Strengthening primary care referral pathways, pathology capacity, radiology access, and affordable treatment availability is essential for improving prostate health outcomes across the continent.

In the Middle East, prostate health is gaining attention as governments invest in tertiary hospitals, cancer centers, screening awareness, and digital health infrastructure, particularly in Gulf countries. Cultural sensitivity, physician-led education, and confidential patient engagement remain central to improving early consultation for urinary symptoms and prostate screening discussions.

Key Group Insights for Prostate Health Priorities

NATO member countries overlap significantly with advanced North American and European healthcare systems, where defense-related health systems, veterans' care, national health services, and occupational medicine channels add distinct routes for prostate screening, survivorship care, and long-term management of aging male populations. These systems can help standardize preventive health engagement, but rural access and service fragmentation remain important challenges.

G7 countries generally lead in clinical research, guideline development, advanced imaging, therapeutic innovation, and reimbursement sophistication, making them influential in setting standards for prostate health diagnostics and treatment pathways. However, even within these high-income systems, disparities remain among rural populations, low-income groups, and racial or ethnic minorities, reinforcing the importance of equitable access and shared decision-making.

BRICS countries represent a highly diverse prostate health landscape, combining large population bases, expanding oncology capacity, growing domestic medical technology capabilities, and persistent access gaps. China, India, Brazil, Russia, and South Africa face the dual challenge of scaling advanced care in major cities while improving early detection, pathology capacity, and affordability in lower-resource settings.

The European Union provides a policy-driven framework for improving prostate cancer detection, evidence-based care, and cross-country quality standards. EU health initiatives increasingly emphasize cancer prevention, early diagnosis, digital health interoperability, and equitable treatment access, although member states vary in reimbursement, MRI availability, specialist workforce, and adoption of advanced therapies.

ASEAN countries are experiencing rising prostate health needs as life expectancy increases and urban healthcare systems expand. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differ widely in specialist density, insurance coverage, and diagnostic infrastructure, creating a mixed landscape where private hospitals often lead adoption of advanced prostate imaging and minimally invasive therapies while public systems prioritize access and affordability. Regional strategies that combine education, primary care screening discussions, and referral partnerships can improve earlier engagement.

The GCC is becoming a more prominent prostate health environment due to government-led healthcare modernization, investment in cancer centers, digital health platforms, and international clinical standards. Countries in the Gulf are also addressing lifestyle-related comorbidities that can complicate men's health management, including obesity, diabetes, and cardiovascular disease. Patient education remains important because cultural reluctance can delay consultation for urinary symptoms or prostate screening discussions.

Key Country Insights in Prostate Health Care

China is rapidly expanding prostate health capabilities as aging accelerates and major hospitals adopt advanced imaging, robotic surgery, and oncology therapies, while awareness and early diagnosis remain lower in many non-urban settings. The United States is a leading prostate health environment, supported by extensive urology networks, advanced imaging availability, high clinical trial activity, and broad adoption of precision oncology tools, although disparities in prostate cancer incidence and mortality among Black men and underserved communities remain a major public health concern.

Japan has a highly aged population, making BPH and prostate cancer management a major clinical priority, with strong diagnostic infrastructure and established urology practice. India faces a growing burden of prostate conditions as longevity rises, with leading metropolitan hospitals offering advanced care but broad challenges in affordability, awareness, and specialist access across rural and lower-income populations.

Germany combines strong urology specialization with advanced diagnostic and surgical capabilities, supported by guideline-based care and established referral systems. The United Kingdom has prioritized evidence-based prostate cancer diagnosis through MRI-led pathways and national health guidance, while public awareness and primary care engagement continue to shape timely referral.

Australia benefits from mature prostate cancer care pathways, public awareness, and advanced imaging access, supported by a strong focus on shared decision-making and survivorship. France has a mature oncology and urology system with broad access to specialist care, and South Korea combines high digital health adoption, strong hospital systems, and increasing access to advanced diagnostics, creating an environment well suited to AI-supported imaging, minimally invasive procedures, and coordinated follow-up care.

Italy and Spain continue to strengthen prostate cancer diagnosis and BPH management through guideline-based care and minimally invasive treatment adoption, although regional health system differences can influence access. Canada combines guideline-led screening discussions with publicly funded care, but wait times and regional access variation can influence diagnostic speed.

Russia has substantial oncology infrastructure in major urban centers but faces regional access variability, especially for advanced diagnostics and specialist-led prostate care. Brazil has one of Latin America's most active prostate health landscapes, with strong awareness campaigns and growing access to oncology and urology services in major cities, though regional inequality remains significant. Mexico is improving awareness and specialist access in urban centers, while affordability and public-sector capacity continue to shape patient pathways.

Actionable Recommendations for Prostate Health Industry Leaders

Industry leaders should prioritize evidence-based prostate health solutions that address the full patient journey, from awareness and screening conversations to diagnosis, treatment, monitoring, and survivorship. First, organizations should invest in clinically validated education programs that reduce stigma and encourage men to seek timely care for urinary symptoms, family history concerns, or screening questions. Messaging should be culturally appropriate and tailored for high-risk groups, including older men and populations with documented disparities in prostate cancer outcomes.

Second, leaders should strengthen partnerships across primary care, urology, radiology, pathology, oncology, pharmacies, payers, and digital health platforms. Integrated referral pathways can reduce delays between abnormal findings, imaging, biopsy, diagnosis, and treatment. Third, innovation strategies should emphasize minimally invasive BPH care, MRI-informed diagnostic pathways, digital symptom monitoring, and AI-supported workflow tools that demonstrate measurable clinical utility.

Fourth, market access and reimbursement strategies should be built around outcomes, safety, health equity, and total cost-of-care value rather than product features alone. Fifth, organizations should prioritize real-world evidence generation, post-market surveillance, and transparent reporting to support trust among clinicians and regulators. Finally, digital prostate health solutions must be designed with privacy, cybersecurity, interoperability, and usability for older adults in mind. The strongest performers will be those that combine medical credibility, patient-centered design, and scalable access models.

Research Methodology for Prostate Health Analysis

This executive summary is developed through a structured secondary research methodology focused on verified, data-backed, and clinically credible sources. The research approach synthesizes evidence from peer-reviewed medical literature, international cancer and urology guidelines, public health agencies, regulatory communications, clinical practice recommendations, hospital care pathway documentation, and epidemiological references from recognized health authorities. The analysis emphasizes prostate cancer, benign prostatic hyperplasia, prostatitis, lower urinary tract symptoms, diagnostic imaging, biopsy pathways, minimally invasive interventions, digital health, artificial intelligence, and regional healthcare access trends.

The methodology applies source triangulation to compare insights across clinical guidelines, population health data, scientific publications, and policy documents. Regional and country-level interpretation considers demographic aging, healthcare infrastructure, specialist access, reimbursement structures, diagnostic capacity, cancer control initiatives, and digital health maturity. Artificial intelligence insights are evaluated through the lens of clinical validation, workflow integration, regulatory oversight, ethical risk, and practical adoption barriers.

To comply with evidence-based standards, the analysis excludes unsupported numerical claims, speculative projections, market sizing, market estimation, market share, and forecasting. It also avoids promotional references and company-specific positioning. The result is a strategic, SEO-optimized executive summary designed to support decision-makers seeking a clear understanding of prostate health trends, care transformation, regional variation, and actionable priorities.

Conclusion: The Future of Prostate Health

Prostate health is moving into a new era defined by earlier detection, precision diagnostics, minimally invasive treatment, digital engagement, and stronger emphasis on long-term quality of life. The clinical burden of prostate cancer, BPH, prostatitis, and urinary symptoms will continue to require coordinated action from healthcare providers, policymakers, payers, technology developers, and patient education stakeholders. The most meaningful progress will come from reducing delays in diagnosis, improving access to specialist care, expanding evidence-based use of imaging and AI, and addressing disparities that affect outcomes across regions and populations.

Regional differences remain significant, with advanced healthcare systems accelerating MRI-led pathways and AI-supported workflows, while many emerging and underserved markets focus on awareness, affordability, referral capacity, and pathology access. Across all settings, patient trust and clinical evidence are essential. Industry leaders that deliver validated, accessible, and equitable prostate health solutions will be best positioned to support better outcomes and more efficient care delivery.

The strategic direction is clear: prostate health must be managed as a continuum rather than a single diagnostic or therapeutic event. By connecting prevention, early consultation, risk-based testing, personalized treatment, remote monitoring, and survivorship support, stakeholders can help transform men's health outcomes while building resilient and patient-centered care models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Health Market, by Product Type

  • 7.1. Introduction
  • 7.2. Diagnostic Kits
    • 7.2.1. Biopsy Devices
    • 7.2.2. Imaging Agents
  • 7.3. Drugs
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormone Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Radiopharmaceuticals
  • 7.4. Imaging Systems
    • 7.4.1. Computed Tomography
    • 7.4.2. Magnetic Resonance Imaging
    • 7.4.3. Positron Emission Tomography
    • 7.4.4. Ultrasound
      • 7.4.4.1. Transabdominal
      • 7.4.4.2. Transrectal

8. Prostate Health Market, by Indication

  • 8.1. Introduction
  • 8.2. Benign Prostatic Hyperplasia
  • 8.3. Prostate Cancer
  • 8.4. Prostatitis

9. Prostate Health Market, by Technology Type

  • 9.1. Introduction
  • 9.2. Digital Pathology
    • 9.2.1. AI Based Analysis
    • 9.2.2. Whole Slide Imaging
  • 9.3. Image Analysis Software
  • 9.4. Molecular Diagnostics
    • 9.4.1. Biomarker Tests
    • 9.4.2. Next Generation Sequencing Panels
    • 9.4.3. Polymerase Chain Reaction Assays

10. Prostate Health Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Care Centers
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals
  • 10.5. Specialty Clinics

11. Prostate Health Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Direct Tender
  • 11.3. Hospital Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Retail Pharmacies

12. Prostate Health Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Prostate Health Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Prostate Health Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Astellas Pharma Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Bayer AG
  • 16.6. Boston Scientific Corporation
  • 16.7. Bracco S.p.A.
  • 16.8. Danaher Corporation
  • 16.9. Eli Lilly And Company
  • 16.10. Intuitive Surgical, Inc.
  • 16.11. Johnson & Johnson Services Inc.
  • 16.12. Koninklijke Philips N.V.
  • 16.13. Lantheus Holdings, Inc.
  • 16.14. MDxHealth SA
  • 16.15. Merck & Co., Inc.
  • 16.16. Myriad Genetics, Inc.
  • 16.17. Nestle S.A.
  • 16.18. Novartis AG
  • 16.19. NOW Health Group, Inc.
  • 16.20. OPKO Health, Inc.
  • 16.21. Pfizer Inc.
  • 16.22. PROCEPT BioRobotics Corporation
  • 16.23. Roche Holding AG
  • 16.24. Sanofi S.A.
  • 16.25. Siemens Healthineers AG
  • 16.26. Teleflex Incorporated
  • 16.27. Telix Pharmaceuticals Limited
  • 16.28. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE HEALTH MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PROSTATE HEALTH MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PROSTATE HEALTH MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PROSTATE HEALTH MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSABDOMINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSABDOMINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSABDOMINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSRECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSRECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSRECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AI BASED ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AI BASED ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AI BASED ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WHOLE SLIDE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WHOLE SLIDE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WHOLE SLIDE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGE ANALYSIS SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMARKER TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOMARKER TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMARKER TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POLYMERASE CHAIN REACTION ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POLYMERASE CHAIN REACTION ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POLYMERASE CHAIN REACTION ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIRECT TENDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIRECT TENDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIRECT TENDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. NATO PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. NATO PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PROSTATE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 284. JAPAN PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 285. JAPAN PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 286. JAPAN PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 356. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 357. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 358. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 359. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 360. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 362. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 365. ITALY PROSTATE HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. ITALY PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. ITALY PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 369. ITALY PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 370. ITALY PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 371. ITALY PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 372. ITALY PROSTATE HE